Member Info for whitto

now on the buy at 2p

upped the price . buying at 1.95 , selling at 2p

Integumen PLC



("Integumen" or "Company")



Labskin partners with University of Aberdeen to test COVID19 anti-viral skin and dental products



Integumen today announces that its subsidiary, Labskin, will begin the immediate testing of anti-viral treatments on Labskin cloned human skin coated with SARS-CoV-2 virus to investigate the use of consumer and dental care products that have the potential to mitigate the risk of transmission of the disease.



Labskin has secured access to the SARS-CoV-2 virus Category 3 laboratory at the University of Aberdeen to assess the strain "SARS-CoV-2 England/2/2020" regarding its transmissibility impact to and from human skin without exposing human volunteers to dangerous clinical trial contamination risk:



· Study the transferability of viral particles from materials to skin

· Assess the ability of the virus to remain infective while on the skin surface

· Quantify the efficacy of mouthwash and dental care products

· Quantify the efficacy of soap washing and hand sanitisers





Gerard Brandon - CEO of Integumen plc, comments:

"COVID-19 has had such a dramatic impact on lives across world, it is important to find products that can help to mitigate the risk of infection, particularly, in professional settings. Labskin is in a unique position to aid the fight against COVID-19 and with the support of the University of Aberdeen, can facilitate testing of the COVID-19 virus on our cloned human skin. We will study the effects of a variety of products and ingredients in the university's secure Containment Level 3 laboratory environment without exposing human volunteers to dangerous and challenging clinical trial contamination risk. The more knowledge we have about SARS-CoV-2 - how it spreads, and more importantly, how to contain that spread - the better equipped to fight this virus we will be."



Skin, transmissibility and infection control trial

The trial involves testing anti-viral treatments on cloned human skin coated with SARS-CoV-2 enabling Labskin to investigate the use of washes and sanitizers and their effectiveness. It will determine:



1. If the virus is transmissible from different surfaces to airways via skin by measuring its viability when recovered from surface(s) to skin.

2. Sanitizers efficiency to kill the virus on skin.

3. The reduction of titer and/or virulence.

Results of the trial are expected in the next six weeks.



Dental practice infection risk

The trial will also investigate consumer and pre-procedural mouthwash dental care products that may mitigate the risk of transmission in dental practices using Labskin grown to mimic the oral and nasal cavities. Given the widespread transmission of SARS-CoV-2, and reports of its spread to health care providers, dental professionals are at high risk of infection and can become potential transmission carriers for the disease. These risk

any mining company who has 14 loi to finance a project is ok with me and by the end of june we should have a better sp . also nickel to look forward too in valueation

As of this post 80 share deals only been done today of which around 72 b4 1pm UK time . Seems odd .

chunky 10 mill buy just shown

mms on the buy at 2.2 .

Tissue Regenix Group plc

CE Mark awarded for OrthoPure XT

Leeds, 1 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, today announces that OrthoPure XT has been awarded a CE Mark.

The CE mark has been awarded for revision of the anterior cruciate ligament (ACL) following re-rupture and additionally, permits use for the reconstruction of other knee ligaments, including multi-ligament procedures following trauma.

OrthoPure XT is a decellularised xenograft ligament that enables tissue regeneration, utilising the Group's patented dCELL® technology which originated from the University of Leeds. The CE mark was obtained following a single arm, non-comparative, prospective study undertaken by the Group over three years. The main outcome was confirmation of safety at two years, with maintenance of knee function.

Gareth Jones, Interim Chief Executive Officer, Tissue Regenix commented: "I am delighted that the company has been successful in being awarded a CE mark for OrthoPure XT, this represents an important milestone in our product portfolio evolution. The Board remains committed to reviewing the overall strategy for both existing and potential products, to ensure cash resources are deployed efficiently and our corporate objectives are met."

could this be another eua

hold onto those valueable shares . this will multibag soon imo

Katoro Gold plc ('Katoro' or the 'Company')



BLYVOOR GOLD TAILINGS PROJECT: EXTENSIVE INTEREST IN PROJECT FUNDING



Katoro Gold plc (AIM: KAT), the AIM listed gold and nickel exploration and development company, is pleased to announce an update with regard to the Company's Blyvoor Joint Venture (the "JV") in respect of the Blyvoor gold tailings project (the "Project").

The recent positive announcement of the Blyvoor Scoping Study saw a significant increase in interest from possible funders, looking at potentially providing the necessary financing to support the construction and development of the Project. The Company was already engaged with a number of potential funders before announcing the Scoping Study results but received significant interest subsequently.

Given the increased interest, particularly post announcement of the Scoping Study results, Katoro Gold Plc, in conjunction with its JV Partner, believes that it is in the best interests of stakeholders to allow for sufficient time to duly entertain and properly consider the funding options/proposals from these potential funders. It is incumbent on the Company to deliver the optimum outcome for its shareholders and with the increase in interest, an additional period will ensure Katoro can ultimately secure the best possible financing option. With this in mind, the JV Partners have agreed to a further extension until 30 June 2020.

Significant progress was made over the past month in advancing the Project at all levels and most notably on the funding initiatives. The Company and its JV Partner will however continue to take a pragmatic approach in the further development of the Project, in what remains an unusual operational environment for contractual finalisation, with specific reference to financing arrangements and associated deadlines, given the COVID-19 pandemic.

Louis Coetzee, Executive Chairman of Katoro, said:

"The JV represents a unique and exciting investment opportunity for the Company with the possibility of significant near-term revenue generation within a very aggressive timeline.

"To have received 14 expressions of interest to date, despite the challenging business conditions that COVID19 has caused, is further validation that the Blyvoor Project is indeed robust and attractive to potential investors. This also demands that the Company take all steps necessary to ensure that it can adequately and responsibly assess, evaluate and consider all available options and possibilities whilst continuing to advance development at pace.

"The Company looks forward to updating shareholders on progress made on the financing deal for the JV Project and appreciate the patience and support that shareholders have shown in recent weeks."

Further background details on the Blyvoor Scoping Study and project are available in the announcements of 30 January 2020 and 07 May 2020 on the Company's website at www.katorogold.com

("Alpha", or the "Company")



Director/PDMR Dealing and Issue of Shares



Alpha Growth plc (LSE: ALGW), the financial services specialist in the growing Senior Life Settlement ("SLS") asset class, is pleased to announce certain directors of the Company have purchased ordinary shares in the Company and the issue of 2,000,000 shares for the agreement with Rajiv Rebello and Colva. This satisfies the condition of the Company's agreement with Colva.



Director/PDMR Dealing

The Company is also pleased to announce that the Directors below have subscribed for the Company's shares as follows:



No. of Shares acquired

Resultant no. of Ordinary Shares

% of Enlarged Issued Share Capital (as enlarged by the Share Issues)

Gobind Sahney

666,667

7,462,500

3.64%

Danny Swick

666,667

2,166,667

1.06%

Jason Sutherland

133,333

133,333

0.07%





Issue of Shares

In relation to the above share issues applications will be made to the Financial Conduct Authority for admission of the new Ordinary Shares to the standard listing segment of the Official List of the Financial Conduct Authority and to London Stock Exchange plc for admission to trading of the New Shares on its main market for listed securities (together, "Admission"). Further announcement will be made as to the date of admission.



Total Voting Rights

Following the issue of the above Shares, the Company's issued share capital will consist of 205,101,673 ordinary shares. Each share has one voting right and no shares are held in treasury; these figures may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.





Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1. Gobind Sahney

2. Daniel Swick

3. Jason Sutherland

2

Reason for the notification

a)

Position/status

1. Chairman

2. Director

3. Director

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alpha Growth plc

b)

LEI

213800T46KFT32KYKR91

4



Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)



Description of the financial instrument, type of instrument

Identification code

Ordinary 0.1p



GB

RNS Number : 1352O
Katoro Gold PLC
28 May 2020

Katoro Gold plc (Incorporated in England and Wales)

(Registration Number: 9306219)

Share code on AIM: KAT

ISIN: GB00BSNBL022

("Katoro" or "the Company")




28 May 2020



Katoro Gold plc ('Katoro' or the 'Company')



HANETI POLYMETALLIC PROJECT - COMMERCIAL UPDATE



Katoro Gold plc (AIM: KAT), the AIM listed gold and nickel exploration and development company, is pleased to provide an update in respect of commercial discussions relating to the Haneti polymetallic project (the 'Project').



BACKGROUND:



On 15 March 2019 Katoro announced an Investment and Option Agreement whereby Power Metal Resources plc (AIM:POW) (formerly African Battery Metals plc) could acquire up to a 35% interest in the Project. This announcement may be viewed through the following link:



https://polaris.brighterir.com/public/katoro_gold/news/rns/story/rdp9o9r



After due diligence POW duly acquired a 25% interest in the Project on 15 May 2019 and held an option to acquire a further 10% through a payment to Katoro of £25,000 by 15 May 2020, with the option period subsequently extended to 31 May 2020 as announced on 15 May 2020.



In recent months Katoro has received approaches with a view to earn-in, joint venture or other similar structures in respect of the Project, with a primary focus on the nickel sulphide potential.



It is apparent that to crystallise the interest shown into a potential commercial transaction, it is preferable, and possibly a requirement, for Katoro and POW to restructure ownership of the Project.



Katoro and POW have therefore agreed to continue to monitor the development of any potential commercial transaction(s), before any final agreement is agreed upon and to in lieu of this, extend POW's option to increase its holding in the Project to 31 August 2020. This will allow both parties the benefit of further discussions and to carefully consider all available options based on additional information.



Louis Coetzee, Executive Chairman of Katoro, said:



"Katoro is in a very busy and positive period at present, particularly in respect of our work on the Blyvoor gold tailings project. We have a good open dialogue with POW and the extra time afforded by this extension gives both parties an opportunity to give due consideration to the interest of all stakeholders and to reach a suitable agreement in a controlled manner.



"Given the external interest shown in Haneti, both Katoro and POW are willing and able to accelerate discussions should this become necessary."



Further background details on the Haneti Project are available in the announcement of 8 October 2019 and on the Companys website at www.katorogold.com.

("Alpha", or the "Company")



Interim Results



Alpha Growth plc (LSE: ALGW), the financial services specialist in the growing Senior Life Settlement ("SLS") asset class, is pleased to announce its results for the interim period ended 29 February 2020.



Gobind Sahney, Chairman of Alpha, commented:

"At the beginning of the year and through February we were quite optimistic about the Company's traction. However, the impact of COVID19 has had an effect on the timing of various counterparties to transact with the Company and this may impact on Company's financial results in FY20 if delays should continue for an extended period of time. However, the Company is confident that, particularly with record low interest rates, continued volatility in the equity markets and the non-correlation of SLS assets, it will be able to continue its strategies in the near terms, and also take advantage of further opportunities as and when they arise for the long term."

The full Interim results for the period ended 29 February 2020 can be downloaded here
http://www.rns-pdf.londonstockexchange.com/rns/1303O_1-2020-5-27.pdf



The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.



For more information, please visit www.algwplc.com or contact the following:

("N4 Pharma", the "Company" or the "Group")



Covid-19 Project Update



Further to the Company's announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on the progress of its Covid-19 proof of concept work for Nuvec®.

As previously announced, the Company appointed Evotec International Gmbh ("Evotec") to undertake the Nuvec® proof of concept work. The Company can confirm that the first phase of the project has been carried out, within the expected timeframe, and that the plasmid DNA has been successfully amplified to produce sufficient material for the rest of the project and has been tested to confirm it matches the required specification. Evotec has also used this batch of the plasmid DNA to express the Covid-19 spike protein to be used as a positive control for the studies. Evotec will now move to the second phase of the work and start the in-vitro testing of Nuvec® as planned, during the first week of June 2020. This phase is expected to last approximately ten weeks.

The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target. Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.

("Eurasia" or "the Company")



APPOINTMENT OF NOMINATED ADVISER AND JOINT BROKER

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

UPDATE ON SUSPENSION OF TRADING ON AIM





Eurasia Mining plc, the palladium, platinum, rhodium, iridium and gold producing company, operating the established West Kytlim Mine in the Urals, and also the operator of the Monchetundra Project comprising two predominately palladium open pit deposits located 3km away from Severonickel, one of Norilsk Nickel's largest base metals and PGM processing facilities, near the town of Monchegorsk on the Kola Peninsula, is pleased to announce the appointment of a nominated adviser and joint broker, the appointment of a non-executive director and an update on the continuing suspension of the Company's shares from trading on the AIM market.



APPOINTMENT OF NOMINATED ADVISER AND JOINT BROKER

Eurasia has appointed SP Angel Corporate Finance LLP ("SP Angel") as its nominated adviser and joint broker with immediate effect. SP Angel is considered an expert in the mining sector and acts for more than 30 mining companies quoted on London Stock Exchange markets.



APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Eurasia Mining plc is pleased to announce the appointment of Iain Rawlinson as a non-executive director of the Company with immediate effect.



Iain is an experienced board member and a strategy consultant. He has a law degree from Cambridge University, is a qualified barrister, and is also an experienced corporate financier having started his career in investment banking with Lazard and Robert Fleming. Between 1994 and 2000 he developed Flemings' corporate finance team in South Africa, which advised on a wide range of mining sector M&A transactions in South Africa and London. He was one of the initial partners of Fleming Family & Partners (FF&P), leading the listing of Highland Gold PLC in 2002, and held a number of senior positions in FF&P until 2005.



Since then, he has held senior independent board appointments in the corporate sector - including Lithic Metals and Energy PLC (2007 to 2009), Dana Petroleum PLC (2005 to 2010), The Monarch Group (2009 to 2014), and Parkmead Group PLC (2010 to 2020), and charities - including Tusk Trust (Trustee from 2002 and Chairman from 2005 to 2013). He is currently a Non-executive Director of the Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (since 2017).



A list of Mr. Rawlinson's current directorships together with those held within the last five years is set out below:



Current Directorships

Previous Directorships/Partnerships over the past 5 years

C. Sibbick & Co. Limited

IBTC Portsmouth

Charles Sibbick Limited

The Parkmead Group Plc

Crowdcaster Limited

VICO Partners Limited

Online Digital Broadcasting Limited

VICO Partners Reserve LLP

Online Radio Broadcasting Limited

Rawlinson Partners Limited

RBCH NHS Foundation Trus

another 2 mill shares sell now showing

that is 6 mill today in big blocks so far

hi 1 million share s just shoeing as sold

("N4 Pharma" or the "Company")



Patent filing update



N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on its patent application for Nuvec®, filed in November 2018 (no. PCT/GB2018/053298).



As announced on 15 November 2018, the Company filed a Patent Cooperation Treaty ("PCT") patent application for improvements made to the manufacturing process for its Nuvec® system. Under the terms of the PCT application process and following conclusion of the national phasing, the Company is now required to make specific applications in the territories in which it wishes to gain patent protection.



In consideration of this, the Company is filing ongoing patent applications in the following territories: Europe (including the UK); USA; Japan; India; Australia; Canada; and China. These additional applications, if successful, claim priority from the Company's United Kingdom patent application number 1718817.8.



Nigel Theobald, Chief Executive Officer of the Company, commented:



"We are seeking additional protection in the territories listed above, which the Board believes would provide maximum patent coverage for our PCT application whilst minimising outgoing expenditure. If the patents are granted in these regions, the Company will maintain its strong commercial protection of Nuvec®."